Travere Therapeutics (TVTX) PT Lowered to $8 at Stifel on "limited Sparsentan's competitive positioning"
Tweet Send to a Friend
(Updated - September 21, 2023 1:46 PM EDT)
Stifel analyst Alex Thompson lowered the price target on Travere Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Alex Thompson lowered the price target on Travere Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
